In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 73 for your search:

Drug:  estramustine phosphate sodium
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase II/III Randomized Study of EM/VBL vs EM for Metastatic Hormone-Refractory Prostate Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: EORTC-30944

Phase III Randomized Study of VBL vs VBL/EM for Metastatic Hormone-Refractory Prostate Cancer (Summary Last Modified 06/96)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: HOG-GU93-1, NCI-V94-0424

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI, Other
Protocol IDs: DM95-231, P30CA016672, MDA-DM-95231, NCI-G96-1044, CDR0000065105, NCT00002855

Phase III Study of Adjuvant Estramustine and Etoposide vs Observation Following Radical Prostatectomy for Stage II, III, or IV Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18-70
Sponsor: NCI
Protocol IDs: CWRU-1894, NCI-G97-1360

Phase III Randomized Study of Docetaxel and Estramustine Versus Mitoxantrone and Prednisone in Patients With Hormone-Refractory, Metastatic Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S9916, CLB-99808, NCCTG-S9916, NCT00004001, S9916

Phase III Randomized Study of Androgen Suppression and Radiotherapy With or Without Subsequent Paclitaxel, Estramustine, and Etoposide in Patients With Localized High-Risk Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: RTOG-9902, RTOG-DEV-1020, RTOG-99-02, NCT00004054

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: ID00-156, U10CA045809, P30CA016672, MDA-ID-00156, NCI-3410, CDR0000068897, 3410, NCT00024167

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069186, RTOG-P-0014, RTOG-DEV-1028, ECOG-RTOG-P-0014, CALGB-RTOG-P-0014, SWOG-RTOG-P-0014, NCT00030654

Phase III Radiotherapy Followed by Estracyt or CTX for Stage B/C/D Prostatic Adenocarcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NPCTG-1000

10.

Phase III DES or Orchiectomy vs CTX/5-FU plus DES or Orchiectomy vs Estracyt for Stage D2 Prostate Cancer without Prior Endocrine Therapy or Chemotherapy

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NPCTG-1300

11.

Phase III MTX vs CTX/ADR vs CTX/5-FU/CACP with Estracyt/CACP as Crossover Therapy for Failures for Hormone-Refractory Metastatic Prostatic Carcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NPCTG-1500

12.

Phase III Estracyt vs CTX After Prostatectomy for Stage B2/C/D1 Prostatic Adenocarcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NPCTG-900

13.

Phase III Randomized Comparison of Estramustine vs MITO in Patients with Metastatic Carcinoma of the Prostate Refractory to Hormonal Treatment (Summary Last Modified 11/88)

Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: EORTC-30865

14.

Phase III Randomized Study of VBL vs VBL/EM in Patients with Metastatic Hormone-Refractory Prostate Cancer (Summary Last Modified 01/94)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-DM-91059, NCI-T92-0007D, T92-0007

15.

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 80
Sponsor: Other
Protocol IDs: CDR0000270970, FRE-FNCLCC-GETUG-12/0203, EU-20238, NCT00055731

16.

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069088, E1899, SWOG-E1899, CALGB-E1899, ECOG-E1899, NCT00027859

17.

Phase I/II Study of Vinorelbine/Estramustine for Hormone-Refractory Prostate Cancer (Summary Last Modified 07/97)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCLA-9411413, NCI-V95-0619

18.

Phase I/II Study of Estramustine/Vinblastine plus 3-Dimensional Conformal Radiotherapy for Poor-Prognosis Nonmetastatic Prostate Cancer (Summary Last Modified 01/99)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: adult
Sponsor: NCI
Protocol IDs: MSKCC-95082, NCI-T96-0049H, T96-0049

19.

Phase I/II Study of Docetaxel in Combination with Estramustine in Patients with Metastatic Adenocarcinoma of the Prostate (Summary Last Modified 04/2000)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPMC-IRB-7386, NCI-V96-0888, NCT00002775

20.

Phase I/II Study of Weekly Paclitaxel in Combination with Estramustine and Carboplatin in Patients with Advanced Prostate Cancer (Summary Last Modified 01/2000)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-97025, NCI-G97-1269

21.

Phase I/II Study of Weekly Intravenous Estramustine in Combination With Paclitaxel and Carboplatin in Patients With Advanced Prostate Cancer (Summary Last Modified 05/2001)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98032, NCI-G98-1448, NCT00003394

22.

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067324, P30CA016087, NYU-9712, NCI-G99-1596, NCT00004105

23.

Phase I/II Randomized Study of Ixabepilone With or Without Estramustine in Patients With Progressive Androgen-Independent Adenocarcinoma of the Prostate

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-01064, MSKCC-01064A, NCI-3634, NCT00025194, 3634

24.

Phase I/II Study of Intravenous Estramustine and Paclitaxel in Patients With Hormone Refractory Prostate Cancer